Dr. Vince Clinical Research Enhances Capabilities with New Obesity Medicine Certification
Dr. Vince Clinical Research Expands CRO Capabilities as William Lavery, MD, PhD, Earns Board Certification in Obesity Medicine
Image: Businesswire
Dr. Vince Clinical Research in Overland Park, Kansas, has expanded its capabilities in early phase clinical trials following William Lavery, MD, PhD, earning board certification in obesity medicine. This certification enhances the organization’s ability to conduct complex obesity-related drug development programs amidst rising obesity rates in the U.S.
- 01William Lavery, MD, PhD, has achieved board certification from the American Board of Obesity Medicine.
- 02Obesity affects 40.3% of U.S. adults, contributing to chronic diseases such as type 2 diabetes and cardiovascular disease.
- 03The certification enhances DVCR's capabilities in conducting early phase clinical research studies focused on obesity.
- 04DVCR's clinical pharmacology unit is noted for its advanced technology and luxurious amenities, aiding in recruitment for complex trials.
- 05The organization aims to innovate beyond first-generation GLP-1 therapies to include broader metabolic treatment strategies.
Advertisement
In-Article Ad
Dr. Vince Clinical Research (DVCR), a contract research organization based in Overland Park, Kansas, has announced a significant enhancement to its early phase clinical trial capabilities. This follows the board certification of William Lavery, MD, PhD, by the American Board of Obesity Medicine. This certification is particularly relevant as obesity continues to affect 40.3% of U.S. adults and is a key factor in chronic diseases like type 2 diabetes and cardiovascular issues. Dr. Lavery stated that his certification will allow DVCR to conduct impactful obesity-related studies, generating faster and higher-quality data for sponsors. DVCR boasts a state-of-the-art clinical pharmacology unit designed to facilitate the recruitment of specialty populations for complex Phase I trials. Additionally, the organization is expanding its research focus beyond traditional GLP-1 therapies to explore new metabolic treatment strategies aimed at improving long-term patient adherence and tolerability.
Advertisement
In-Article Ad
The expansion of DVCR's capabilities will enhance local clinical research efforts in obesity medicine, potentially leading to new treatment options.
Advertisement
In-Article Ad
Reader Poll
How important do you think obesity medicine is in today's healthcare landscape?
Connecting to poll...
Read the original article
Visit the source for the complete story.